References
- World Health Organization. The global burden of disease. Geneva: WHO, 2003
- Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999;39(Suppl 2):S20–6
- Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259–87
- Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001;10:1831–45
- Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002;59: 1084–8
- Diener HC. Pharmacological approaches to migraine. J Neural Transm Suppl 2003;64:35–63
- Silberstein SD. Migraine. Lancet 2004;363:381–91
- Saper JR. What matters is not the differences between triptans, but the differences between patients. Arch Neurol 2001;58:1481–3
- Stark S, Spierings ELH, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000;40:513–20
- Färkkilä M, Olesen J, Dahlöf CGH, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003;23:463–71
- Diener HC, Gendolla A, Gebert I, et al. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache 2005;45:874–82
- Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache 2005;45:156–62
- Dahlöf CGH. Infrequent or non-response to oral sumatriptan does not predict response to other triptans – review of four trials. Cephalalgia 2006;26:98–106
- Rapoport AM, Tepper SJ. Triptans are all different. Arch Neurol 2001;58:1479–80
- Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633–58
- Dahlöf C, Tfelt-Hansen P, Massiou H, et al. Dose finding, placebo-controlled study of oral almotriptan in the treatment of acute migraine. Neurology 2001;57:1811–17
- Dahlöf C, Pascual J, Dodick DW, et al. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia 2006;26:400–8
- Dodick, DW. A review of the clinical efficacy and tolerability of almotriptan in acute migraine. Expert Opin Pharmacother 2003;4:1157–63
- Iglesias-Diez F, Straube A, Zanchin G. Patient preference in migraine therapy: a randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J Neurol 2007;254:242–9
- Diener HC. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients with previous poor response to sumatriptan 50 mg. Curr Med Res Opin 2005;21: 1603–10
- Massiou H, Pradalier A, Donnet A, et al. Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. Eur Neurol 2006;55:198–203
- Geraud G, Lanteri-Minet M, Lucas C, et al. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004;26:1305–18
- Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007;115:34–40
- Diener HC. Consistent efficacy, tolerability and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice. Headache 2005;45: 624–31